Nedham & Company在火箭制药公司上保持“买”评级,价格目标为52美元。 Needham & Company maintains a "buy" rating on Rocket Pharmaceuticals with a $52 price target.

尼德姆公司在其他分析师的积极反中,在火箭制药 (NASDAQ: RCKT) 保持了"买入"评级,目标价为52美元. Needham & Company has maintained a "buy" rating on Rocket Pharmaceuticals (NASDAQ: RCKT) with a $52 price target, amid positive feedback from other analysts. 公司的平均评级是“机动购买” 协商一致目标为51.75美元 The average rating for the company is "Moderate Buy" at a consensus target of $51.75. 与此同时,美国火箭实验室(NASDAQ:RKLB)的股份在花旗集团将价格目标提高到13美元之后达到了52周的高位,而拥有71.78%股票的机构投资者的支持日益增加。 Meanwhile, Rocket Lab USA (NASDAQ: RKLB) shares reached a 52-week high after Citigroup raised its price target to $13, with increasing support from institutional investors, who own 71.78% of the stock.